The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

Novo Nordisk shares plunged 18% Friday afternoon and were headed for their worst intraday drop since April 2002. However, ...

The results are a “worst-case scenario” for Novo, said Markus Manns, portfolio manager at mutual funds firm Union Investment, a Novo and Lilly shareholder. Novo Nordisk CEO Lars Joergensen ...

Novo Nordisk (NVO) stock dropped more than 15% on Friday following an update on its obesity drug that fell short of expectations. Headlines from the company’s press release revealed that Novo ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Novo Nordisk’s shares fell by the most on record ... from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to ...

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...

Bad news for Novo Nordisk (NYSE: NVO) Friday was good news for Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX), its two main rivals in the field of weight loss drugs. This morning ...